InnoCare Pharma Limited (HKG:9969)
Hong Kong · Delayed Price · Currency is HKD 12.66
+0.06 (0.48%)
Feb 13, 2026, 4:08 PM HKT
InnoCare Pharma Revenue
InnoCare Pharma had revenue of 383.89M CNY in the quarter ending September 30, 2025, with 38.09% growth. This brings the company's revenue in the last twelve months to 1.43B, up 58.75% year-over-year. In the year 2024, InnoCare Pharma had annual revenue of 1.01B with 36.68% growth.
Revenue (ttm)
1.43B CNY
Revenue Growth
+58.75%
P/S Ratio
16.28
Revenue / Employee
1.21M CNY
Employees
1,176
Market Cap
25.40B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.01B | 270.91M | 36.68% |
| Dec 31, 2023 | 738.54M | 113.13M | 18.09% |
| Dec 31, 2022 | 625.40M | -417.63M | -40.04% |
| Dec 31, 2021 | 1.04B | 1.04B | 76,368.70% |
| Dec 31, 2020 | 1.36M | 117.00K | 9.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genscript Biotech | 6.50B |
| Shanghai Henlius Biotech | 6.35B |
| Zai Lab | 3.44B |
| Shanghai Junshi Biosciences | 2.71B |
| Duality Biotherapeutics | 2.38B |
| Biocytogen Pharmaceuticals (Beijing) | 1.30B |
| Keymed Biosciences | 955.73M |
| Ascentage Pharma Group International | 428.02M |